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A proangiogenic micromilieu is associated with a worse 
prognosis in systemic lymphoma. Hence, targeting the 
tumour microenvironment and its vasculature has evol-
ved as a promising novel treatment strategy. The role of 
tumour neoangiogenesis in cutaneous B-cell lymphoma, 
however, has not yet been elucidated. Therefore, we exa-
mined the expression of vascular endothelial growth fac-
tor (VEGF) and its receptors VEGFR-1 and VEGFR-2, 
as well as microvessel density by immunohistochemistry 
in paraffin-embedded specimens of different subtypes of 
primary cutaneous B-cell lymphomas, systemic diffuse 
large B-cell lymphoma, and cutaneous B-cell pseudo-
lymphoma. Primary cutaneous large B-cell lymphoma 
(PCLBCL) were characterized by significantly higher 
intratumoral expression levels of VEGF and its receptors 
in comparison with the indolent lymphoma sub types. 
Moreover, PCLBCL exhibited significantly higher intra-
tumoral microvessel counts. Our study provides eviden-
ce that the most aggressive subtype of cutaneous B-cell 
lymphoma, PCLBCL, is characterized by a proangi-
ogenic micromilieu. Key words: angiogenesis; microves-
sel density; VEGF; cutaneous B-cell lymphoma; tumour 
microenvironment.
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According to the World Health Organization/European 
Organisation for Research and Treatment of Cancer 
(WHO/EORTC) classification, primary cutaneous B-
cell lymphomas (PCBCL) are subdivided into 3 major 
groups; namely, primary cutaneous follicle centre 
lymphoma (PCFCL), primary cutaneous marginal zone 
lymphoma (PCMZL), and primary cutaneous large 
B-cell lym phoma (PCLBCL) (1). While PCFCL and 
PCMZL show an indolent clinical course with an excel-
lent prognosis, PCLBCL represents a more aggressive 
lymphoma. In contrast to diffuse PCFCL, in which 
small to large cleaved centrocytes dominate the tumour 
infiltrate, PCLBCL is histologically characterized by 
large sheets of centroblasts and immunoblasts. Age and 
tumour extent represent negative prognostic factors in 
PCLBCL. Moreover, impaired prognosis is observed 
when skin lesions are present at the lower extremities, 
and this has given the name to this lymphoma subgroup 
PCLBCL, leg-type (PCLBCL-LT)), a hitherto incomple-
tely understood phenomenon. Similar to systemic dif-
fuse large B-cell lymphoma (sDLBCL), gene expression 
profiling in PCLBCL has provided a molecular basis for 
the subdivision into this biologically distinct subgroup 
(2). Hierarchical clustering of PCLBCL, leg-type and 
PCFCL based on B-cell signatures demonstrated that 
PCLBCL-LT shows expression profiles resembling 
that of activated B cells. In sDLBCL, these expression 
patterns, indicative of different stages of B-cell diffe-
rentiation, have strong prognostic significance (3, 4). 
Besides molecular profiling of the tumour cells 
themselves, their interaction with the tumour micro-
environment is currently the focus of interest in lymp-
homa research (5–7). In this context, Lenz et al. (8) 
have reported that the gene expression profile of the 
non-tumour cells significantly predicts biological beha-
viour, treatment response and survival in patients with 
sDLBCL. The so-called stromal-1 signature is related 
to extracellular matrix deposition and histiocytic infil-
tration. This genetic pattern portends a good prognosis. 
On the contrary, the denotated stromal-2 signature is 
associated with a poor prognosis. This signature compri-
ses an overexpression of genes encoding proteins such 
as platelet endothelial cell adhesion molecule-1 (PE-
CAM-1/CD31) or the receptor for vascular endothelial 
growth factor (VEGFR-2). Hence, it primarily reflects 
angiogenesis. Accordingly, high intratumoral micro-
vessel density (MVD) (9) as well as overexpression of 
vascular endothelial growth factor (VEGF) and other 
proangiogenic cytokines are assigned a major role for 
the tumour biology of different types of systemic lym-
phoma (10–12). As a consequence, therapies targeting 
the microenvironment have gained increasing attention 
and tumour angiogenesis has evolved as an attractive 
molecular target for novel therapeutic strategies (6). 
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The angiogenic switch is essential for a continuous 
tumour growth beyond a certain threshold (13). The 
complex process of tumour neoangiogenesis is governed 
by a plethora of countervailing humoral and cellular 
factors, which either induce or repress angiogenesis 
(14). The multifunctional cytokine vascular endothelial 
growth factor VEGF-A (commonly referred to as VEGF) 
represents the leading proangiogenic factor. It is expres-
sed by tumour as well as stromal cells belonging to the 
tumour microenvironment. Of note, beyond its paracrine 
effects on endothelial cells VEGF may serve as an 
autocrine growth factor for the tumour cell itself (10). 
In PCBCL the impact of the tumour microenviron-
ment, especially of the tumour-associated microvas-
culature, has not been systematically analysed to date. 
Therefore, we used immunohistochemical analyses to 
evaluate whether subtypes of PCBCL can be distinguish-
ed with respect to microvascular density and expression 
of VEGF with its auto- and paracrine functions. indeed, 
all of these parameters were elevated in the more aggres-
sive lymphoma subtype PCLBCL-LT and indicated a 
worse prognosis for this entity. Factors associated with 
angiogenesis could therefore serve as novel molecular 
biomarkers in cutaneous B-cell lymphoma and may 
represent attractive therapeutic targets in the future. 
MATERIALs AnD METHODs
Patients
Paraffin-embedded tissue of skin of 12 patients with PCLBCL-
LT, 15 patients with PCFCL, 17 patients with PCMZL, 9 patients 
with cutaneous B-cell rich pseudolymphoma (PL) (including 
lymphadenosis cutis benigna) and secondary cutaneous in-
filtrates of 13 patients with sDLBCL were obtained from the 
archives of the Department of Dermatology and the institute 
of Pathology, University of Wuerzburg. Tissues were collected 
during a time period from 1999 to 2011. Patients alive provided 
informed consent prior to entering the study according to the 
guidelines of the institutional ethics committe. Patients with 
cutaneous B-cell lymphoma were staged according to the WHO/
EORTC classification, those with systemic B-cell lymphoma 
according to the Ann Arbor system. The clinical characteristics 
of the lymphoma patients are summarized in Table i. 
Immunohistochemical studies
Immunohistochemical analysis. immunohistochemistry for 
CD31, VEGF, VEGFR-1 and VEGFR-2 was performed on 5-μm 
tissue sections, which were placed on glass slides. For immuno-
histochemistry, tissue sections were deparaffinized in xylol and 
rehydrated in graded alcohol. For antigen retrieval, slides were 
overlaid with antigen retrieval solution (Dako, Hamburg, Ger-
many) and incubated in saturated steam for 20 min. For staining, 
slides were incubated with a murine polyclonal anti-CD31/PE-
CAM-1 antibody (Dako, Hamburg, Germany), which highlights 
both blood and lymphatic endothelial cells, rabbit polyclonal 
anti-VEGF antibody (VEGF (A-20), Santa Cruz, Heidelberg, 
Germany), which recognizes the VEGF165,121 and 189 splice variants, 
rabbit polyclonal anti-VEGFR-1 antibody (Flt1, spring Biosci-
ence, Pleasanton, CA, USA) and rabbit polyclonal anti-VEGFR-2 
antibody (Flk-1, Lab Vision, Thermo science, Cheshire, uk). 
For detection of VEGFR-1 and -2, Ultravision Quanto Detec-
tion system based on HRP-polymer (TL-125-QHL, Lab Vision, 
Thermos Science, Chesire, UK) was used, for visualization of 
VEGF and CD31 the Dako Real Detection System based on HRP 
(K5003, Dako, Hamburg, Germany). Control antibody staining 
using polyclonal rabbit antiserum was performed accordingly 
for VEGF, VEGFR-1 and VEGFR-2 using appropriate protocols. 
Evaluation of immunohistochemical staining. For evaluation 
of MVD, slides were scanned in the light microscope at × 40 
magnification and so-called hot spots were identified. MVD was 
determined by counting the number of CD31+ microvessels per 
measurement field at × 200 magnification (× 20 lens, × 10 ocular, 
measurement field of 0.3136 mm2) using an Olympus BX45 
microscope, as described (15). A microvessel was defined as 
any distinct CD31+ cell cluster with or without a vessel lumen. 
The cell surface molecule CD31, which is expressed both by 
blood as well as by lymphatic endothelium, was chosen for the 
immunohistochemical analyses because CD31/PECAM-1 is 
one of the genes included in the formerly described stromal-2 
signature (8). Counting was performed at least in 2 different 
representative fields of the tumour. The microvessel counts 
in the analysed areas were averaged and denoted MVD. To 
evaluate differences in microvasculature dependent on body 
location among patients with PCLBCL-LT, MVD inside the 
tumour and the non-involved surrounding tissue was assessed 
separately for location at the leg and non-leg location. 
A visual semiquantitative scoring system was used for evaluating 
the staining results of VEGF and VEGFR-1 and -2. in case of 
VEGF, less than 5% cellular staining inside the tumour was scored 
negative (i.e. 0), 5–30% staining was scored weakly positive (i.e. 
1), 30–60% staining intermediately positive (i.e. 2) and more than 
60% staining strongly positive (i.e. 3). Due to lower frequencies of 
VEGFR-1- and VEGFR-2- positive cells, 5–20% of stained cells 
was graded as weakly (i.e. 1), 20–40% as intermediately (i.e. 2) 
and > 40% staining as strongly positive (i.e. 3). Physiologically 
VEGF/VEGFR-positive structures, such as keratinocytes, endothe-
lial cells or sweat glands, served as internal controls (16). images 
of the immunohistological staining were acquired using a zeiss 
Axiophot microscope and Axiocam digital camera. 
Statistical analysis
Statistical analysis was performed with Prism Graph Version 
3.0. Survival curves were estimated using log-rank test and 









Patients 12 15 17 13
Mean age, years 70 55 48 65
Female 6 6 9 7
Male 6 9 8 6
Multi-locular lesions at time 
of diagnosis 6 7 7 12
Solitary lesion at time of 
diagnosis 6 8 10 1
Best response CR after first-
line therapy 6 10 11 5
Overall response CR 5 11 11 6
Mean progression-free 
survival, months 12 25 26 26
Mean overall survival, months 27 60 60 43
CR: complete remission; PCLBCL-LT: primary cutaneous large B-cell 
lymphoma, leg-type; PCFCL: primary cutaneous follicle centre lymphoma; 
PCMZL: primary cutaneous marginal zone lymphoma; sDLBCL: systemic 
diffuse large B-cell lymphoma.
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presented in Kaplan–Meier curves. Multivariate analysis was 
performed according to the Cox proportional hazards regres-
sion model. The χ2 test for independence was used to test for 
correlations between categorical variables. Test results with 
p-values ≤ 0.05 were considered significant.
REsuLTs
PCLBCL-LT exhibits a proangiogenic micromilieu
The patient characteristics are presented in Table i. 
Microvascular density was assessed to determine if 
tumour-associated vasculature correlates with the 
prognostic subtype of cutaneous B-cell lymphoma. 
All analysed tumours showed a significantly higher 
microvascular density than the surrounding normal 
tissue (p ≤ 0.001). However, the tumour vascularity 
varied within and between the different subgroups (Fig. 
1a). PCLBCL-LT (Fig. 1b) and sDLBCL displayed a 
significantly higher vascular density (p ≤ 0.001) compa-
red with PCFCL (Fig. 1c), PCMZL and PL. The score 
of intratumoral microvessel density was comparable 
among the subgroups PL, PCFCL and PCMZL. In ac-
cordance with high MVD PCLBCL-LT and sDLBCL 
showed significantly higher frequencies (p ≤ 0.0001) of 
VEGF-positive tumour cells within the tumour than the 
other lymphoma subtypes and pseudolymphoma (Fig. 
2 a, b). MVD both inside the tumour and in the sur-
rounding tissue did not significantly differ for location 
at the leg and other locations in PCLBCL-LT (Fig. 3a). 
However, VEGF scores were higher in tumours and 
surrounding non-involved tissue when located in the 
lower extremities (Fig. 3 b, c).
Increased expression of VEGFR-1 and VEGFR-2 in 
tumour cells from PCLBCL-LT
in order to elucidate whether VEGF may potentially act 
on lymphoma cells in an autocrine manner, we analysed 
the expression pattern of VEGF receptors VEGFR-1 
and VEGFR-2. immunohistochemical scores for 
VEGFR-1 and VEGFR-2 expression were significantly 
higher in PCLBCL-LT and sDLBCL in comparison 
with PCFCL, PCMZL and PL (p ≤ 0.001) (Fig. 2 c–f). 
Microvessel density and prognosis in PCLBCL-LT
Overall survival (OS) and progression-free survival 
(PFs) of 12 patients with PCLBCL-LT being treated 
with R-CHOP ± radiotherapy were correlated with 
MVD (Fig. 3 d, e). There was no statistically significant 
difference between the 2 groups, and confirmation in a 
larger cohort is required. 
Fig. 1. (a) Microvascular density in the different subtypes of 
cutaneous B-cell lymphoma, B-cell pseudolymphoma and diffuse 
large B-cell lymphoma was determined by counting CD31 positive 
vascular structures. Vessel count/0.3136 mm2 is separately indicated 
for the central part of the tumour (left column) and the surrounding 
non-involved tissue (right column). Primary cutaneous large B-cell 
lymphoma, leg-type (PCLBCL-LT) and systemic diffuse large B-cell 
lymphoma (sDLBCL) show significant higher microvessel density 
(MVD) than the indolent lymphoma subgroups. ***p ≤ 0.001. (b) 
Example of CD31-staining demonstrating high density of tumour-
associated blood vessels in PCLBCL-LT. Magnification ×200. (c) 
intermediate MVD in primary cutaneous follicle centre lymphoma 
(PCFCL) as assessed by immunohistochemistry with an antibody 
against CD31. Original magnification × 200. 
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Fig. 2. Primary cutaneous large B-cell lymphoma, leg-type (PCLBCL-LT) and systemic diffuse large B-cell lymphoma (sDLBCL) exhibit significantly 
higher scores of (a) vascular endothelial growth factor (VEGF) and its receptors (c) VEGFR-1 and (d) VEGFR-2 than primary cutaneous follicle centre 
lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL) and pseudolymphoma (PL). ***p ≤ 0.001. Representative photomicrographs 
showing immunohistochemical stains for (b) VEGF, (c) VEGFR-1 and (e) VEGFR-2, in a representative specimen of the same patient with PCLBCL-LT. 
Original magnification ×400. Control antibody staining (inset). Magnification × 400.
Fig. 3. Microvessel density (MVD) and expression of vascular endothelial growth factor (VEGF) expression was assessed dependent on body site. (a) 
MVD in primary cutaneous follicle centre lymphoma-leg-type (PCLBCL-LT) inside the tumour (black columns) and in the non-involved surrounding 
tissue (white columns) did not differ for location at the leg and non-leg location. VEGF score inside (b) the lymphoma infiltrate and (c) the surrounding 
tissue of PCLBCL-LT showed significantly higher values for location at the legs. no statistical difference is detected for low or high MVD on (d) overall 
and (e) progression-free survival in PCLBCL-LT.
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DiSCUSSiOn
In various systemic B-cell neoplasms increased tumour 
neoangiogenesis was found to be associated with a 
more aggressive behaviour and a poor prognosis (17). 
Recently, the underlying molecular basis has been 
delineated in sDLBCL (8). To date, no study has sys-
tematically addressed this topic in PCBCL. Therefore, 
we aimed to evaluate the role of tumour neoangioge-
nesis for the prognostically different subtypes PCFCL, 
PCMZL and PCLBCL-LT.
in the current study, all analysed specimens, both 
malignant lymphomas and benign pseudolymphomas, 
showed a signifcantly higher mean MVD compared 
with the surrounding normal tissue. Physiological 
angiogenesis is known from benign conditions, such 
as wound healing, hair growth cycle, acute and chronic 
inflammation (18). Likewise, it is herein observed in 
reactive inflammatory pseudolymphoma. Inflamma-
tory processes induce vessel dilatation and enhanced 
permeability. Angiogenic response to inflammation 
promotes a reversible enlargement of pre-existing ves-
sels (19) rather than sprouting of new vessels. 
On the other hand, new vessel formation is induced 
via aberrant and constant overexpression of proangioge-
nic cytokines due to oncogene-driven gene expression. 
in our study, the microvessel count did not discriminate 
between benign inflammatory processes, such as PL 
and the indolent cutaneous lymphoma subtypes PCFCL 
and PCMZL. Only one prior study has to date assessed 
MVD in different types of indolent primary cutaneous 
B-cell lymphoproliferative disorders with comparable 
results (20). However, concerning the more aggres-
sive lymphoma subtypes characterized by a large cell 
morphology (PCLBCL-LT, sDLBCL), significantly 
higher levels of mean MVD were detected. This is in 
line with previous studies in systemic B-nHL, where 
more unfavourable lymphoma subtypes showed higher 
MVD (9, 21). In systemic B-cell lymphomas the extent 
of MVD distinguishes between reactive benign lympha-
denopathy and lymph nodes enlarged due to infiltration 
by non-Hodgkin’s lymphoma (22). Hence, the assess-
ment of MVD can serve as an important adjunct in the 
diagnostic algorithm for the diagnosis of large B-cell 
lymphoma of the skin (23). 
To elucidate the pathophysiological background of 
neoangiogenesis in PCBCL, we analysed the protein 
expression of VEGF. As VEGF-A represents the leading 
proangiogenic mediator for regulating the complex 
process of neoangiogenesis (24), we restricted our 
analysis to this major cytokine. no difference in VEGF 
expression was observed in PL and indolent PCFCL 
and PCMZL corresponding to equal MVD in these sub-
types. These findings may indicate that a proangiogenic 
milieu probably does not gain relevance until advanced 
stages of malignant transformation. In PCLBCL-LT 
and sDLBCL, VEGF was significantly more strongly 
expressed, which corresponded to a higher vascularity. 
Similar studies in systemic haematological disorders 
have demonstrated higher levels of VEGF expression 
in tissue and circulation in more aggressive lymphoma 
subtypes (21, 25). To date, only 2 case reports have 
demonstrated elevated levels of VEGF in tissue and 
blood of a single patient with PCLBCL-LT (26, 27). 
The exact nature of VEGF overexpression in 
PCLBCL-LT is so far unknown. One may speculate 
that higher VEGF expression in tumour cells of this 
lymphoma subtype may result from aberrant oncogenic 
signalling (28). PCLBCL-LT exhibits, among others, an 
upregulation of bcl-2 and c-myc (2, 29). Beside anti-
apoptotic and prosurvival properties (30), these factors 
are known to promote tumour angiogenesis (31–35). 
Hence, overexpression of bcl-2, which was detected in 
>90% of our PCLBCL-LT specimens (data not shown) 
and upregulation of c-myc may thus, at least partially, 
explain the observed VEGF induction in tumour cells 
of PCLBCL-LT. Of note, in our study VEGF expression 
was not only restricted to lymphoma cells. in addition, 
various stromal cells stained positive. This underlines 
the importance of the tumour microenvironment for the 
angiogenic response (36).
Induction of VEGF gene expression in response to hy-
poxia (37) strongly depends on the proliferative activity 
of the tumour (38). In this context, high expression of 
hypoxia inducible factors (HIF-1α, HIF-1β) and conse-
cutive VEGF upregulation (39, 40) was demonstrated in 
aggressive lymphomas (41, 42). Intratumoral hypoxic 
conditions are supposed to be especially relevant for 
PCLBCL-LT. Its rapidly growing, ulcerating and ne-
crotic tumours predominantly arise at body sites with 
restricted blood and oxygen supply, such as the lower 
legs (43). In chronic venous insufficiency, lipoder-
matosclerosis and peripheral arterial ischaemia of the 
lower extremities upregulation of VEGF was observed 
in response to hypoxia and inflammation (44–46). Like-
wise, in our study, higher amount of VEGF expression 
was observed in different specimen derived from the 
lower extremities. Hence, overexpression of VEGF 
in soft tissue of the lower extremities may establish a 
protumorigenic micromilieu and provides a rationale 
explanation for the prognostically unfavourable location 
at the legs in PCLBCL-LT.
To elucidate whether VEGF may exert beyond its 
paracrine, i.e. proangiogenic, also autocrine, i.e. protu-
morigenic, properties in PCBCL (10), we analysed the 
expression of VEGFR-1 and -2. In skin, VEGFR-1 and 
-2 are physiologically expressed on endothelial cells, ad-
nexal structures and keratinocytes (16). Both receptors 
were also aberrantly upregulated on the tumour cells. 
Of interest, expression of both tyrosine kinase receptors 
was significantly higher in PCLBCL-LT and sDLBCL 
than in the indolent lymphoma subtypes and PL. A 
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functional autocrine loop with constitutive mitogenic 
self-stimulation in these more aggressive lymphomas 
may be the consequence. That could contribute to the 
high proliferation index, as observed in PCLBLT; ac-
cordingly, all analysed PCLBCL-LT showed a high 
proliferation index, as determined by Mib1 staining 
(data not shown). 
PCLBCL-LT with higher mean baseline MVD (> 22.4 
CD31+ microvessels/0.3136 mm2) exhibited a slightly 
worse prognosis; however, without statistically sig-
nificant difference. Traditional prognostic parameters 
for PCLBCL-LT include age, extent and location of 
skin lesions and expression of bcl-2, MuM-1 (29, 47). 
Further studies will clarify whether the easily-applicable 
assessment of VEGF- and VEGFR-expression as well 
as MVD by immunohistochemical staining with CD31 
may provide a useful tool to more accurately predict the 
prognosis of PCBCL and to deduce the adequate thera-
peutic regimen. In systemic large B-cell lymphoma and 
other lymphoma subtypes antiangiogenic therapeutic 
modalities are already applied in clinical routine, and 
clinical studies are currently evaluating antiangiogenic 
therapies, including bevacizumab, endostar and thali-
domide (www.clinicaltrials.gov). 
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